# Vitamin E (Mixed Tocopherols & Tocotrienols) - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Extensive biochemical literature establishing lipid membrane protection and neuroprotection with mixed isomers.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **89/100**
- **Evidence Quality Tier**: **silver**
- **Human Clinical Evidence Strength**: 88/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 84/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Peroxyl radical scavenging in lipophilic membrane bi-layers

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 67 mg (100 IU)
- **Recommended Timing**: Dinner with fat-containing meal
- **Administration Type**: supplement
- **Recommended Biomarkers to Monitor**: skin_clarity, cellular_longevity

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: High-dose blood thinning agents (monitor INR/PT)
- **Safety Profile**: High - Keep under 400 IU (268 mg) daily for long-term health.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Mixed Tocotrienols Promote Skin Fibroblast Renewal and UV Protection** [PMID: 21873130]
   - Link: https://pubmed.ncbi.nlm.nih.gov/21873130/
2. **Tocotrienols and Tocopherols in Lipid Peroxidation Chain Breaking** [PMID: 23759240]
   - Link: https://pubmed.ncbi.nlm.nih.gov/23759240/
3. **Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis: The PIVENS Randomized Controlled Trial** [PMID: 20427778]
   - Link: https://pubmed.ncbi.nlm.nih.gov/20427778/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Vitamin E (Mixed Tocopherols & Tocotrienols) on LongevityReviews](https://longevityreviews.org/modalities/vitamin-e)
- **Last Evidence Calibration**: 2026-08-09
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.